Loading
A phase 2 trial of Visugromab, Nivolumab, Docetaxel in non-small-cell lung cancer and small-cell lung cancer, run by CatalYm GmbH, now recruiting.
Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC is a phase 2 interventional study registered as NCT07246863 by CatalYm GmbH, with 131 participants planned, started 2025-10-07 and due to reach its primary completion in 2029-10-01. Interventions recorded: Visugromab RDE (recommended dose for expansion), Visugromab 6mg/kg, Nivolumab, Placebo Saline Infusion, Docetaxel. Conditions listed: Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Visugromab, CatalYm, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Visugromab, CatalYm, Nivolumab, Immune checkpoint inhibitors.
Shares Visugromab, CatalYm, Immune checkpoint inhibitors.
Shares Visugromab, CatalYm, Nivolumab, Immune checkpoint inhibitors.
Shares Docetaxel, Small-cell lung cancer, Cytotoxic chemotherapy, Immune checkpoint inhibitors.
Shares Docetaxel, Small-cell lung cancer, Cytotoxic chemotherapy, Non-small-cell lung cancer.
Shares Docetaxel, Small-cell lung cancer, Cytotoxic chemotherapy, Non-small-cell lung cancer.
Shares Docetaxel, Small-cell lung cancer, Cytotoxic chemotherapy, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/